Dr Rollag and others conducted the study which showed that people with bleeding disorders treated with factor products from "a relatively small and stable pool of domestic, non-paid donors" and the overall proportion with Hepatitis C was 41%, and for those with severe Haemophilia A or B it was 64% or 67%, respectively.